Vaxcyte, Inc. (PCVX)

63.71 +3.16 (+5.22%) At close: 04:00PM EDT

Vaxcyte, Inc.

825 Industrial Road
Suite 300
San Carlos, CA 94070
United States
650 837 0111
https://vaxcyte.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 254

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Grant E. Pickering M.B.A.	Co-Founder, CEO & Director	1.13M	1.2M	1968
Mr. Andrew L. Guggenhime M.B.A.	President & CFO	820.81k	1.9M	1968
Mr. James Wassil M.B.A., M.S.	Executive VP & COO	521.05k	943.62k	1969
Mr. Mikhail Eydelman J.D.	Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary	684.62k	930.64k	1982
Dr. Ashish Khanna M.B.A., Ph.D.	Co-Founder	N/A	N/A	1972
Dr. Jeff Fairman Ph.D.	Co-Founder & VP of Research	N/A	N/A	1964
Ms. Elvia Cowan	Senior VP of Finance & Principal Accounting Officer	N/A	N/A	1973
Ms. Janet Graesser	Senior Vice President of Corporate Communications & Investor Relations	N/A	N/A	N/A
Ms. Whitney Jones	Chief People Officer	N/A	N/A	N/A
Mr. Paul W. Sauer M.B.A.	Senior Vice President of Process Development & Manufacturing	608.96k	N/A	1961

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Corporate governance

Vaxcyte, Inc.’s ISS governance QualityScore as of 29 April 2024 is 6. The pillar scores are Audit: 2; Board: 5; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.